{"schema":"sb.node.v1","id":"sb:e/456fb88d459950f8a5770955","kind":"entity","label":{"text":"amgen","locale":"en"},"identity":{"anchor":"label:en:amgen","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T23:33:39.923351+00:00","snapshot":"deploy 760ddad45b80bcc53aa1d7d4c2af0dae14c85403"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":85,"separatePublishers":31,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":11,"of":11,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-06-21","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.176: about 82% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","biotech_pharma"],"activeDays":32,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/ab8b67194b705ca1217fa72b","kind":"observation","label":"IAM · 2026-09-30 · BMS’s Opdivo patent suit against Amgen adds to eventful 2026 for biosimilar spats","url":"https://www.iam-media.com/article/bmss-opdivo-patent-suit-against-amgen-adds-eventful-2026-biosimilar-spats"},{"id":"sb:o/fad1c52c1b201cba19d8a513","kind":"observation","label":"Fierce Biotech · 2026-09-30 · Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody","url":"https://www.fiercebiotech.com/biotech/amgen-reveals-6-point-drop-lupus-severity-behind-phase-2-win-horizon-antibody"},{"id":"sb:o/12f722d11a0e966447fe8640","kind":"observation","label":"Clinical Trials Arena · 2026-09-24 · First of Amgen’s Phase III Sjögren’s disease trials succeeds","url":"https://www.clinicaltrialsarena.com/news/first-of-amgens-phase-iii-sjogrens-disease-trials-succeeds/"},{"id":"sb:o/74eafeef9e44faa6ab070a8d","kind":"observation","label":"Endpoints News · 2026-09-23 · Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal","url":"https://endpoints.news/amgens-phase-3-sjogrens-win-novartis-900m-radioligand-deal/"},{"id":"sb:o/83cd5177fc443c57e6955d7c","kind":"observation","label":"MarketBeat News Feed · 2026-09-22 · Erste Group Bank Brokers Reduce Earnings Estimates for Amgen","url":"https://www.marketbeat.com/instant-alerts/estimates-erste-group-bank-brokers-reduce-earnings-estimates-for-amgen-2026-09-22/"},{"id":"sb:o/1ef985be2d7c5c253733dc72","kind":"observation","label":"BioPharma Dive · 2026-09-12 · Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use","url":"https://www.biopharmadive.com/news/imdelltra-bridgebio-oncology-evommune-encoded-tectora/830056/"},{"id":"sb:o/a7a8b0b237b919371b1ae725","kind":"observation","label":"24/7 Wall St. · 2026-09-10 · Here Are Thursday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Amgen, AngloGold Ashanti, Caterpillar, Chewy, Meta Platforms, Novartis, NVIDIA, SK hyn…","url":"https://247wallst.com/investing/2026/09/10/here-are-thursdays-top-wall-street-analyst-research-calls-advanced-micro-devices-amgen-anglogold-ashanti-caterpillar-chewy-meta-platforms-novartis-nvidia-sk-hynix-and-more/"},{"id":"sb:o/04d880ed839ad1a6ca403f73","kind":"observation","label":"Fierce Pharma · 2026-09-09 · Amgen’s DLL3-targeted Imdelltra scores overall survival win in first-line small cell lung cancer","url":"https://www.fiercepharma.com/pharma/amgen-dll3-targeted-imdelltra-scores-overall-survival-win-first-line-small-cell-lung-cancer"},{"id":"sb:o/eac17a08723d32d0de382bac","kind":"observation","label":"24/7 Wall St. · 2026-09-09 · Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%","url":"https://247wallst.com/investing/2026/09/08/amgen-falls-10-as-novartis-trial-failure-clouds-a-cholesterol-drug-class-nvs-stock-drops-14/"},{"id":"sb:o/b099700e365b1e7de08c5854","kind":"observation","label":"MarketBeat News Feed · 2026-09-07 · HighTower Advisors LLC Sells 4,063 Shares of Amgen Inc. $AMGN","url":"https://www.marketbeat.com/instant-alerts/filing-hightower-advisors-llc-sells-4063-shares-of-amgen-inc-amgn-2026-09-07/"}],"cursor":"c1.eyJpZCI6InNiOmUvNDU2ZmI4OGQ0NTk5NTBmOGE1NzcwOTU1IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDIzOjMzOjM5LjkyMzM1MSswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with merck (38 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/dfea7994dfc1bf2dbba07eef"},{"kind":"relation","label":"co-mentioned with eli lilly (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1ddf1058e1ca2036a35075a7"},{"kind":"relation","label":"co-mentioned with astrazeneca (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/271fee09f0995473793a9538"},{"kind":"relation","label":"co-mentioned with novartis (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c93b03375e8b448be8f489cb"},{"kind":"relation","label":"co-mentioned with pfizer (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/15d6877b87c3e94acbb28973"},{"kind":"relation","label":"co-mentioned with roche (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5ba4d2d7fd9bda06be6dc7a9"},{"kind":"relation","label":"co-mentioned with bristol myers squibb (23 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3276a00caed3e0d56152973f"},{"kind":"relation","label":"co-mentioned with fda (22 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/efced2e055c4330611e13491"},{"kind":"relation","label":"co-mentioned with abbvie (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/cc6e4d440f9cc15cfdbcffca"},{"kind":"relation","label":"co-mentioned with bayer (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/92c961c97b5daa296e8839cf"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/456fb88d459950f8a5770955","mcp":"traverse {\"id\":\"sb:e/456fb88d459950f8a5770955\"}","page":"/entity/amgen/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/456fb88d459950f8a5770955\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/456fb88d459950f8a5770955\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/456fb88d459950f8a5770955\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/456fb88d459950f8a5770955\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}